These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 32712436)
1. Getting under the skin: The role of CDK4/6 in melanomas. Guo L; Qi J; Wang H; Jiang X; Liu Y Eur J Med Chem; 2020 Oct; 204():112531. PubMed ID: 32712436 [TBL] [Abstract][Full Text] [Related]
2. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy. Kong Y; Sheng X; Wu X; Yan J; Ma M; Yu J; Si L; Chi Z; Cui C; Dai J; Li Y; Yu H; Xu T; Tang H; Tang B; Mao L; Lian B; Wang X; Yan X; Li S; Guo J Clin Cancer Res; 2017 Nov; 23(22):6946-6957. PubMed ID: 28830923 [No Abstract] [Full Text] [Related]
3. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. Sheppard KE; McArthur GA Clin Cancer Res; 2013 Oct; 19(19):5320-8. PubMed ID: 24089445 [TBL] [Abstract][Full Text] [Related]
4. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition. Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667 [TBL] [Abstract][Full Text] [Related]
6. Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer. Sobhani N; D'Angelo A; Pittacolo M; Roviello G; Miccoli A; Corona SP; Bernocchi O; Generali D; Otto T Cells; 2019 Apr; 8(4):. PubMed ID: 30959874 [TBL] [Abstract][Full Text] [Related]
7. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104 [TBL] [Abstract][Full Text] [Related]
8. Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy. Xu L; Cheng Z; Cui C; Wu X; Yu H; Guo J; Kong Y J Transl Med; 2019 Jul; 17(1):245. PubMed ID: 31358010 [TBL] [Abstract][Full Text] [Related]
9. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Anders L; Ke N; Hydbring P; Choi YJ; Widlund HR; Chick JM; Zhai H; Vidal M; Gygi SP; Braun P; Sicinski P Cancer Cell; 2011 Nov; 20(5):620-34. PubMed ID: 22094256 [TBL] [Abstract][Full Text] [Related]
10. Targeting CDK4/6 in patients with cancer. Hamilton E; Infante JR Cancer Treat Rev; 2016 Apr; 45():129-38. PubMed ID: 27017286 [TBL] [Abstract][Full Text] [Related]
11. Targeting cyclin-dependent kinase 4/6 as a therapeutic approach for mucosal melanoma. Shi CJ; Xu SM; Han Y; Zhou R; Zhang ZY Melanoma Res; 2021 Dec; 31(6):495-503. PubMed ID: 34483306 [TBL] [Abstract][Full Text] [Related]
12. An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma. Teh JL; Purwin TJ; Greenawalt EJ; Chervoneva I; Goldberg A; Davies MA; Aplin AE Cancer Res; 2016 Sep; 76(18):5455-66. PubMed ID: 27488531 [TBL] [Abstract][Full Text] [Related]
13. Fluorescent peptide biosensor for monitoring CDK4/cyclin D kinase activity in melanoma cell extracts, mouse xenografts and skin biopsies. Prével C; Pellerano M; González-Vera JA; Henri P; Meunier L; Vollaire J; Josserand V; Morris MC Biosens Bioelectron; 2016 Nov; 85():371-380. PubMed ID: 27203461 [TBL] [Abstract][Full Text] [Related]
14. Ablation of epidermal RXRα in cooperation with activated CDK4 and oncogenic NRAS generates spontaneous and acute neonatal UVB induced malignant metastatic melanomas. Chagani S; Wang R; Carpenter EL; Löhr CV; Ganguli-Indra G; Indra AK BMC Cancer; 2017 Nov; 17(1):736. PubMed ID: 29121869 [TBL] [Abstract][Full Text] [Related]
15. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression. Piccinin S; Doglioni C; Maestro R; Vukosavljevic T; Gasparotto D; D'Orazi C; Boiocchi M Int J Cancer; 1997 Feb; 74(1):26-30. PubMed ID: 9036865 [TBL] [Abstract][Full Text] [Related]
16. Distinct sets of genetic alterations in melanoma. Curtin JA; Fridlyand J; Kageshita T; Patel HN; Busam KJ; Kutzner H; Cho KH; Aiba S; Bröcker EB; LeBoit PE; Pinkel D; Bastian BC N Engl J Med; 2005 Nov; 353(20):2135-47. PubMed ID: 16291983 [TBL] [Abstract][Full Text] [Related]
18. Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6. Yoshida A; Lee EK; Diehl JA Cancer Res; 2016 May; 76(10):2990-3002. PubMed ID: 26988987 [TBL] [Abstract][Full Text] [Related]